Zufferey Pascal
Rev Med Suisse. 2016 Mar 9;12(509):512, 514-6.
The only biological treatments recognized and reimbursed for spondylarthritis in Switzerland are anti TNF. Other effective agents in rheumatoid arthritis were found to be of little use in this indication. Fortunately, in recent years appeared biological molecules blocking cytokines involved in new pathways of inflammation in particular that of IL7. They have been very effective against psoriasis and have a high potential in psoriatic arthritis and spondylarthritis. In parallel, synthetic small molecules capable of modulating the production of intracellular cytokines begin to be marketed. They also are potentially active in the same rheumatic diseases. The purpose of this article is to review these new drugs, in particular to review the progress of their development and commercialization status.
在瑞士，唯一被认可并纳入报销范围的脊柱关节炎生物治疗药物是抗TNF药物。其他在类风湿关节炎中有效的药物在该适应症中作用甚微。幸运的是，近年来出现了一些生物分子，它们能够阻断参与新炎症途径（特别是IL7途径）的细胞因子。这些生物分子对银屑病非常有效，在银屑病关节炎和脊柱关节炎中具有很大潜力。与此同时，能够调节细胞内细胞因子产生的合成小分子开始上市。它们在相同的风湿性疾病中也可能具有活性。本文旨在综述这些新药，特别是回顾它们的研发进展和商业化状况。
